Today's Rundown Roche-backed Arch Oncology gets off $50M round for anti-CD47 cancer work Biotech IPOs keep coming as Gilead-backed Hookipa Pharma guns for $86M U.K. biotech funding climbs 35% in fast start to 2019 Agios blood cancer drug lead jumps ship to Aprea Therapeutics Inflazome grabs Fox Foundation funding for Parkinson’s R&D IBM tech explains why some cells die in response to treatment and others don’t Featured Story | | | Monday, March 25, 2019 Just weeks after kick-starting its phase 1 test, Arch Oncology has gathered $50 million in financing to help see its immuno-oncology asset through the clinic. |
|
|
Top Stories Monday, March 25, 2019 Appetite for biotech IPOs still appears high as Hookipa Pharma filed for a meaty public offering. It aims to use the cash boost toward its midstage cancer and infectious disease work. Monday, March 25, 2019 British biotechs raised £182 million ($240 million) in venture funding during the first quarter of 2019. The figure is up 35% from this time last year, showing VCs are continuing to invest in U.K. biotechs despite political uncertainty. Monday, March 25, 2019 Swedish p53 cancer biotech Aprea Therapeutics has nabbed former Agios senior medical director Eyal Attar as its senior vice president and chief medical officer. Monday, March 25, 2019 The Michael J. Fox Foundation has provided funding to inflammatory disease biotech Inflazome. The funding will support research intended to improve the chances that Inflazome will succeed in the clinic. Monday, March 25, 2019 Several cancer drugs work by promoting “apoptosis,” or programmed cell death. Researchers at Mount Sinai, working with IBM, found a link between responses to those treatments and mitochondria, the elements of cells that produce energy. | This week's sponsor is Covance. | | | Advancing a Diabetes Multi-Registration Program
Learn how Covance helped a sponsor who wanted to get all sites for a 2,700 patient study up and running as quickly as possible. Covance leveraged their proprietary historical investigator performance database to see which investigators outperformed their peers on a consistent basis and had the capacity to run multiple studies at the same time. Download the Case Study now. |
Resources Sponsored by: Veradigm Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care. Sponsored by: Outer Edge Technology Software end of life puts you at risk for data breaches, business disruption and liability. Support for Microsoft SQL Server 2008/2008 R2 and Windows Server 2008/2008 R2 ends on July 9, 2019 and January 14, 2020, respectively. Learn how you can turn these risks into a strategic business advantage. Sponsored by: AlphaSense From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve. Sponsored by: InterSystems Analytics using patients’ real-time longitudinal laboratory results, and claims data, yielded higher value information and new revenue streams for TriCore reference laboratories. Sponsored by: InterSystems Whitepaper on leveraging normalized real-world patient data to streamline clinical trials, reduce delays and lower costs. Sponsored by: Patheon, part of Thermo Fisher Scientific The Right Partner Can Improve Flexibility and Mitigate Risks from Forecast Inaccuracy in Biomanufacturing. Sponsored by: Patheon, part of Thermo Fisher Scientific Download this whitepaper to learn more. Sponsored by: ON24 Which HCP Touchpoints and channels are yielding the best results in today’s digital world? Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. BioBasics: Biotech For The Non-Scientist March 28-29, 2019 | Boston, MA Drug Development Immersion April 3-4, 2019 | Philadelphia, PA BioBasics: Biotech For The Non-Scientist May 8-9, 2019 | New York, NY Drug Development Immersion May 16-17, 2019 | Boston, MA 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA FierceBiotech Executive Breakfast at BIO 2019 – Getting Real: The Changing Tide on Real-World Evidence in Drug Development June 5, 2019 | Philadelphia, PA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! Calling Europe – Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 